MADISON, November 12, 2026 — The U.S. Food and Drug Administration has approved the OncoMate MSI Dx Analysis System as a companion diagnostic to identify patients with MSI-H solid tumors for treatment with pembrolizumab.
How the Test Guides Therapy Selection
The OncoMate MSI Dx test is designed to help doctors select patients who may benefit most from pembrolizumab therapy. It works by identifying a specific biomarker known as microsatellite instability-high (MSI-H) in solid tumor tissue. According to the FDA, the approval covers the use of this test to find MSI-H or mismatch repair-deficient (dMMR) tumors in adult and pediatric patients with unresectable or metastatic cancer that has progressed after prior treatment and who have no satisfactory alternative options.
The Science Behind the Test
The OncoMate MSI Dx system is a qualitative multiplex polymerase chain reaction (PCR) assay. It evaluates five mononucleotide microsatellite loci in a patient’s tumor tissue and compares them to a normal sample from the same person. Tumors with instability in two or more of these markers are classified as MSI-H. This molecular testing provides a clear, evidence-based method to determine a tumor’s MSI status, which is a key factor in deciding whether immunotherapy like pembrolizumab is an appropriate treatment option.
Regulatory History and Broader Applications
The test’s regulatory journey reflects its expanding role in precision oncology. The FDA previously cleared the OncoMate MSI Dx system as the first PCR-based molecular diagnostic to identify colorectal cancer patients who may benefit from further testing for Lynch syndrome. In a more recent application, the agency approved it as a companion diagnostic to identify patients with microsatellite stable (MSS) endometrial carcinoma who may benefit from a combination of pembrolizumab and lenvatinib. This approval applies to the United States and its territories, and the technology has also received regulatory clearance in the European Union and China.
Clinical Evidence and Patient Eligibility
The full FDA approval for pembrolizumab in MSI-H/dMMR solid tumors was supported by pooled data from more than 30 cancer types across three clinical trials: KEYNOTE-164, KEYNOTE-158, and KEYNOTE-051. In these trials, pembrolizumab demonstrated a pooled objective response rate of 33.3%, with a median duration of response of 63.2 months. The encouraging part of this data is the potential for long-lasting responses in a subset of patients. Patients should discuss their eligibility for pembrolizumab and the role of biomarker testing with their oncologist.
Impact on Future Treatment Decisions
This approval strengthens the foundation of precision oncology by providing a specific, validated tool to match patients with a therapy most likely to help them. The OncoMate MSI Dx test connects diagnostic results to treatment strategies, working alongside pharmaceutical collaborators and clinicians to support informed therapeutic choices. For patients facing advanced cancer, this approach offers a path to more personalized care. The encouraging part is that this test helps ensure the right patient gets the right treatment at the right time. As with any medical decision, patients should talk to their doctor to understand their specific situation and treatment options.
Sources
- FDA Approves OncoMate MSI Dx For Pembrolizumab in MSI-H Tumors | Targeted Onc – Immunotherapy, Biomarkers, and Cancer Pathways
- FDA Approves OncoMate MSI Dx as Pembrolizumab Companion Diagnostic in MSI-H Solid Tumors | CancerNetwork
- FDA Approves Promega OncoMate® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA® in MSI-High Solid Tumors
- FDA Approves Companion Diagnostic for Pembrolizumab in MSI-H Solid Tumors | OncLive
- Microsatellite Instability Test Gains FDA Approval for Immunotherapy Selection
- Promega's MSI Technology Receives FDA Approval – Startup and Tech News – Madison Startups
Photo: Lucas Vasques / Unsplash (Unsplash License)
